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 Calcium-sensing receptor 
 2 e landmark report by Brown  et al. of the 
cloning and characterization of the cal-
cium-sensing receptor (CaSR) in bovine 
parathyroid glands launched the continu-
ously evolving and exciting story of CaSR 
and calcimimetics. 1 2 e initial characteri-
zation in the parathyroid gland implicated 
the CaSR as an essential element in the 
physiologic machinery responsible for the 
maintenance of calcium homeostasis. 2 e 
CaSR is a 121-kilodalton, low-aG  nity G 
protein-coupled cell-surface receptor that 
senses extracellular levels of calcium ion 
and enables the cell to respond to small 
changes in extracellular ionized calcium 
concentrations. In the chief cells of the 
parathyroid gland, the CaSR regulates the 
secretion of the parathyroid hormone 
(PTH) in response to changes in calcium 
concentrations; small increases in ambient 
calcium concentrations result in signi3 -
cant reduction in PTH. 
 In addition to being present abundantly 
on the surface of the parathyroid cells, the 
CaSR is also present on the calcitonin-
secreting C cells of the thyroid, in multiple 
sites in the kidney, in bone, and in various 
other organ tissues. Activation of the CaSR 
in the thick ascending limb results in sig-
nificant reduction of the paracellular 
transport of the divalent ions calcium and 
magnesium and disturbs the countercur-
rent mechanism, leading to reduction in 
urinary concentration ability. In the inner 
medullary collecting duct, calcium stimu-
lation of the CaSR inhibits the actions of 
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 The new role of calcimimetics as 
vasculotropic agents 
 Ziyad  Al-Aly 1 , 2 
 The discovery of the calcium-sensing receptor (CaSR) and the 
development of calcimimetics have provided new insights into calcium 
homeostasis and new therapeutic opportunities for parathyroid-related 
disorders. However, the CaSR is also implicated in various other cellular 
processes, and the translational applications of calcimimetics may not 
be exclusively calcium-centric. Koleganova  et al. describe a novel role for 
calcimimetics as vasculotropes, which provides the impetus for further 
studies to characterize their effects on vascular biology. 
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vasopressin, leading to increased free water 
clearance and polyuria. Independently of 
its effect on the parathyroid gland, the 
CaSR seems to be involved in the regula-
tion of bone homeostasis; a recent study 
showed that it is critical for chondrogen-
esis and growth plate development. 2 e 
CaSR may also play a PTH-independent 
role in the renal production of calcitriol, 
and gastrointestinal calcium absorption. 
 Beyond its e; ects on calcium homeo-
stasis and water metabolism, the CaSR has 
also been found in multiple organ tissues 
that are not directly implicated in systemic 
calcium regulation, including the intes-
tines, pancreas, brain, heart, and the 
arterial wall ( Figure 1 ). At these sites, 
the CaSR is involved in the regulation of 
peptide and hormonal secretion (insulin, 
gastrin, and vascular endothelial growth 
factor), ion-channel and transporter func-
tion, and a number of important cellular 
processes, such as gene expression, prolif-
eration, di; erentiation, apoptosis, chemo-
taxis, and localization of hematopoietic 
stem cells to the endosteal niche. 
 Calcimimetics 
 2 e discovery of the CaSR facilitated the 
development of calcimimetics, a class of 
agents that modulate the function of the 
CaSR. Type II calcimimetics change the 
structural conformation of the receptor 
and, in the presence of calcium, act as 
positive allosteric modulators of the CaSR, 
rendering it more sensitive to ambient 
calcium concentration and subsequently 
resulting in reduction of PTH secretion in 
a dose-dependant manner. R-568 was the 
3 rst calcimimetic to be tested in clinical 
trials, but because of its low bioavailabil-
ity and numerous interactions with other 
drugs, further clinical testing was not pur-
sued. A second-generation calcimimetic, 
AMG-073 (cinacalcet), was developed and 
shown to have signi3 cant clinical applica-
tions in the management of hypercalcemia 
in patients with parathyroid cancer as well 
as patients with secondary hyperparathy-
roidism on renal replacement therapy. Be-
fore the introduction of calcimimetics in 
clinical practice, most treatment modali-
ties used in the management of second-
ary hyperparathyroidism in patients with 
kidney disease (vitamin D and calcium-
based phosphate binders) resulted in some 
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elevation in serum calcium concentra-
tions, and the use of the so-called standard 
therapy (phosphate binders with or with-
out vitamin D) resulted in a small percent-
age of patients meeting the National Kid-
ney Foundation Kidney Disease Outcomes 
Quality Initiative targets for calcium, phos-
phorus, calcium – phosphorus product, 
and PTH — a shortcoming that may have 
an implication for mortality. 2 2 e addi-
tion of calcimimetics and non-calcium-
based phosphate binders to our repertoire 
of medical therapeutics has increased the 
proportion of patients whose parameters 
fall within the recommended range. 
 E5 ect of calcimimetics beyond 
mineral metabolism 
 Guided by the notion that PTH is a uremic 
toxin and that it acts as a permissive factor 
for the development of hypertension, car-
diac 3 brosis, microvessel disease, and dys-
lipidemia, Ogata  et al. found that lowering 
PTH by parathyroidectomy or by the use 
of the calcimimetic R-568 results in similar 
improvement in blood pressure, serum low-
density lipoprotein cholesterol, albuminu-
ria, glomerulosclerosis, tubulointerstitial 
damage, and — serendipitously — quantita-
tive cardiac stereology parameters. 3 2 ese 
observations were further validated by 
experiments showing that both calcitriol 
and R-568 lower PTH levels to the same ex-
tent and are similarly e; ective in reducing 
albuminuria, glomerular volume, podocyte 
volume, the degree of foot process fusion, 
and glomerular basement membrane 
thickness in subtotally nephrectomized 
rats. 4 All the above taken together strongly 
suggests that the e; ect of calcimimetics on 
renal functional and structural parameters 
is related to their e; ect on PTH. 
 In experimental animal models, the 
CaSR has been identi3 ed in endothelial 
cells and possibly in vascular smooth mus-
cle cells and adventitial cells. In  ex vivo 
experiments, the activation of the CaSR 
seems to regulate the myogenic tone in rat 
subcutaneous arteries, and treatment with 
cinacalcet results in a concentration-
dependent vasodilatation of isolated pre-
contracted aortae. 5 Recent evidence also 
suggests that the CaSR agonist spermine 
induces the production of nitric oxide in 
aortic endothelial cells and that this e; ect is 
abrogated by CaSR knock-down. 6 Moreover, 
 in vivo experiments showed that despite 
causing an initial transient rise in blood 
pressure, the calcimimetic R-568 had a 
signi3 cant and sustained antihypertensive 
e; ect in uremic rats. 7 
 Calcimimetics also seem to prevent 
extraskeletal calci3 cation associated with 
either calcitriol or paricalcitol in uremic 
rats with secondary hyperparathyroidism. 
Lopez and collaborators examined so1 -
tissue calcification in uremic rats with 
secondary hyperparathyroidism and 
showed that calcitriol and paricalcitol 
induce extraskeletal calci3 cation and that 
coadministration of calcitriol or parical-
citol with a calcimimetic (AMG-641) 
reduces soft-tissue calcification. 8 In 
another study, Henley  et al. also found 
that calcitriol induces aortic calci3 cation 
in uremic rats with secondary hyper-
parathyroidism, but in their experiments the 
coadministration of cinacalcet with calci-
triol did not reduce the calcitriol-induced 
aortic calci3 cation. 9 2 e failure of cinacal-
cet to reduce calci3 cation in this study is 
probably due to the higher dose of calci-
triol used in these experiments (250 – 280 
versus 80  ng / kg in the experiments of 
Lopez  et al. 8 ) and suggests perhaps that 
the ability of calcimimetics to modulate 
the e; ect of vitamin D on the vasculature 
is dependent on the dose of vitamin D. 
 Koleganova  et al. 10 (this issue) now fur-
ther extend the above observations and 
describe the e; ect of the calcimimetic R-
568 and non-hypercalcemic, low-dose 
calcitriol (30  ng / kg) on vascular remode-
ling in rats subjected to either sham oper-
ation or subtotal nephrectomy. 2 ey 3 nd 
that while R-568 reduced remodeling, and 
calci3 cation in the vascular wall, calcitriol 
treatment induced proliferation of vascu-
lar smooth muscle cells and endothelial 
cells and increased wall thickening and 
calci3 cation of the vascular wall. 
 Whether the e; ect of the calcimimetic 
R-568 on vascular wall remodeling and vas-
cular calci3 cation is related to its e; ect on 
systemic calcium homeostasis or is a direct 
e; ect on the vasculature is not clear yet. 
However, it is interesting to note that there 
was no di; erence in serum calcium, phos-
phorus, or PTH between uremic animals 
treated with calcitriol and those treated with 
R-568, yet the e; ects of calcitriol and R-568 
on the vasculature were distinctly di; erent 
and in opposite directions. 2 ese 3 ndings 
suggest that the vasculotropic e; ects of R-
568 may be independent of its effect on 
PTH and mineral metabolism — a notion 
that is widely di; erent from the one derived 
from the experiments showing that the 
e; ect of calcimimetics on renal functional 
and structural parameters is related to their 
e; ects on PTH. 
 Calcimimetics and clinical outcomes 
 To date, there is no prospective rand-
omized clinical trial evaluating the e; ect of 
adding calcimimetics to standard therapy 
on cardiovascular outcomes and mortality 
in patients with secondary hyperparathy-
roidism. In retrospective analysis of pooled 
data from four randomized controlled 
trials in which patients with secondary 
hyperpara-thyroidism receiving standard 
care were randomized to receive standard 
care and the calcimimetic cinacalcet or 
standard care alone, Cunningham  et al. 
analyzed the e; ect of addition of cinacalcet 
on parathyroidectomy, long bone fractures, 
hospitalization, mortality, and self-report-
ed health-related quality of life outcomes 
and found that treatment with cinacalcet 
was associated with less risk of parathy-
roidectomy, fracture, and cardiovascular 
hospitalization and some improvement in 
quality-of-life measures. 11 However, the 
study did not show any e; ect on mortality. 
It is important to note that the study was 
a retrospective analysis of four di; erent 
studies with relatively short follow-up and 
a consequently limited number of events, 
and that these studies were not designed to 
examine long-term outcomes. 
 2 ere are at least two ongoing major tri-
als that aim to evaluate the e; ects of cina-
calcet on cardiovascular outcomes. 2 e 
randomized, double-blind, placebo-con-
trolled EValuation Of Cinacalcet HCl 
2 erapy to Lower CardioVascular Events 
(EVOLVE) trial is currently under way in 
422 study locations globally and aims to 
evaluate the e; ects of treatment with cina-
calcet on cardiovascular events and death 
in approximately 3883 chronic kidney dis-
ease patients with secondary hyper-
parathyroidism receiving maintenance 
hemodialysis. 2 e ADVANCE trial is a 
randomized open-label clinical trial that 
aims to investigate the e; ect of cinacalcet 
in combination with low-dose vitamin D 
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on the progression of coronary artery cal-
cification scores in 330 patients with 
chronic kidney disease on hemodialysis 
with base-line coronary artery calci3 ca-
tion score of at least 30. 
 Surrogate end points versus clinical 
outcomes 
 2 e demonstration by Koleganova  et al. 10 
that calcimimetics modulate vascular re-
modeling in uremia highlights the fact that 
pharmaceutical interventions o1 en exert 
systemic e; ects beyond their immediate 
or classical target. 2 e past few years have 
been a very exciting time in medicine, and 
the explosion of clinical trials has provided 
numerous valuable opportunities to under-
stand the e; ects of drugs on disease out-
comes. 2 e recent trials showing possible 
adverse cardiovascular outcomes with ros-
iglitazone, lack of improvement in carotid 
artery intima – media thickness and possibly 
increased risk of cancer with ezetimibe, and 
increased mortality with the use of eryth-
ropoietin-stimulating agents to achieve 
certain hemoglobin levels underscore the 
fact that although certain pharmaceutical 
agents may have bene3 cial e; ects on surro-
gate markers, such as reduction in glycated 
hemoglobin, reduction in low-density li-
poprotein cholesterol, or an increase in 
hemoglobin levels, these bene3 cial e; ects 
do not always translate to improvement in 
clinical outcomes (morbidity, hospitaliza-
tions, mortality). 2 e disconnect between 
the e; ect on surrogate markers and the ef-
fect on clinical outcomes is probably related 
to the fact that many drugs exert numerous 
bene3 cial pleiotropic or harmful o; -tar-
get e; ects that impact clinical outcomes, 
a phenomenon that is overlooked when 
the focus of the clinical trial is a surrogate 
end point. Focusing only on the e; ect of a 
drug on surrogate markers fails to capture 
the overall e; ect of the pharmaceutical in-
tervention on the overall condition of the 
patient. Another consideration is that the 
target of the normalization of surrogate 
markers in certain groups of patients may 
not be adequate. Normalizing blood pres-
sure in old patients or normalizing hemo-
globin in dialysis patients may lead to worse 
clinical outcomes. A higher than  ‘ normal ’ 
blood pressure in elderly patients and low 
levels of hemoglobin in patients with kid-
ney disease, for example, may represent 
an adaptive response, and correction to a 
 ‘ normal ’ level may disturb this adaptive re-
sponse and lead to poor outcomes. 
 2 ese observations further emphasize 
that surrogate markers, although impor-
tant in demonstrating the efficacy of a 
certain pharmaceutical intervention, are 
not enough, and there is a real need for 
studies examining real clinical outcomes. 
It is time that the United States Food and 
Drug Administration shi1  the primary 
eG  cacy end point for mineral and bone 
disorders in chronic kidney disease from 
surrogate markers to clinical outcomes. 
 Finally, the study by Koleganova  et al. 10 
provides further insight into the role of 
calcimimetics in vascular biology and 
some of the background necessary to 
explore the potential translational applica-
tions of calcimimetics to vascular health. 
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 Figure 1 |  The calcium sensing receptor calcium homeostasis and beyond.  The calcium-sensing receptor is ubiquitously expressed in multiple 
organ tissues and is involved in multiple functions beyond calcium homeostasis. The availability of calcimimetics allows further characterizations of 
these functions and their implications in health and disease. 
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 Teles and co-workers 1 (this issue) 
present experimental data addressing 
some of these issues. Rats with streptozo-
tocin-induced diabetes were treated with 
conventional (50  mg / kg / d) and extremely 
high (500  mg / kg / d) doses of the angi-
otensin receptor blocker (ARB) losartan. 
In contrast to most diabetic nephropathy 
studies, in which treatment is initiated 
around the time of onset of diabetes, the 
authors tested the e; ects of losartan in 
rats starting 10 months a1 er induction of 
diabetes, at a time when structural 
glomerular lesions were already present. 
Notably, this experimental design may 
more closely mimic the clinical situation, 
where nephroprotective treatment is not 
initiated until the patient exhibits incipi-
ent or overt nephropathy. 
 Treatment with losartan reduced pro-
teinuria to levels observed in control ani-
mals and led to regression of mesangial 
expansion to below pretreatment levels. In 
contrast, more advanced lesions (de3 ned 
by synechiae to Bowman ’ s space, capillary 
loop occlusion, more abundant deposition 
of periodic acid-Schiff (PAS)-positive 
material, and segmental hyalinization) 
were not a; ected. Representative phot-
omicrographs depicting these stages and 
the e; ects of RAS inhibition, from similar 
groups of rats studied in our laboratory, 
are shown in  Figure 1 (unpublished data). 
However, although treatment did not 
induce regression of these more advanced 
changes, it largely prevented the develop-
ment of new lesions. 2 us, the authors 
provide valuable information suggesting 
that dramatic reduction of proteinuria is 
associated with regression of mesangial 
expansion, without affecting more 
advanced glomerular lesions. 
 Teles  et al. 1 are to be commended for 
carefully di; erentiating between the vari-
ous morphologic parameters. Much of the 
existing literature regarding  ‘ regression ’ is 
far less precise. The term is often used 
clinically to refer to reduction in urinary 
albumin excretion rate, sometimes from 
microalbuminuria back down into the 
normal range. However, the vast majority 
of these studies do not include structural 
information, leaving open the important 
question of whether the reduction in 
urinary albumin excretion will have 
long-term significance with respect to 
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 Inhibition of the renin –
 angiotensin system: is more 
better ? 
 Sharon  Anderson 1 , 2 and  Radko  Komers 1 
 Inhibitors of the renin – angiotensin – aldosterone system (RAS) exert 
beneficial effects in diabetic nephropathy, but the possibility of 
regression of existing renal lesions remains to be investigated. Teles  et al. 
tested the effects of the RAS inhibitor losartan in rats starting 10 months 
after induction of diabetes, when glomerular lesions were already 
present. They linked the reductions of proteinuria with regression of 
mesangial expansion. More advanced lesions were not affected. There 
were no dose – response renal effects of losartan. 
 Kidney International (2009)  75, 12 – 14.  doi: 10.1038/ki.2008.556 
 Inhibition of the renin – angiotensin –
 aldosterone system (RAS) plays a pivotal 
role in the prevention and treatment of 
diabetic nephropathy. A myriad of studies, 
including large multicenter randomized 
trials with patients at various stages of dia-
betic nephropathy, has well documented 
that treatment with RAS inhibitors can 
slow the progressive decrease in glomeru-
lar 3 ltration rate, reduce proteinuria and 
microalbuminuria, prevent transition 
from one stage of nephropathy to 
another, and reduce cardiovascular mor-
tality and morbidity. However, despite 
these documented beneficial effects 
of RAS inhibitors in diabetic patients 
with overt nephropathy, reversal of the 
progressive course of this disorder or at 
least long-term stabilization of renal 
function is diG  cult to achieve, and many 
patients still progress to end-stage renal 
disease. 
 Several reasons have been postulated 
for unsatisfactory therapeutic responses 
to RAS inhibition in some patients, 
including incomplete inhibition of the 
RAS, lack of effects on structural hall-
marks of diabetic nephropathy, and the 
question of reversibility of established 
renal lesions in these patients. 
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